June 15, 2026

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

Conexiant

June 12, 2026

Language Barriers Linked to Cancer Treatment Delays

Texas registry data point to neighborhood-level vulnerability as a possible target for improving timely colorectal cancer care.

Conexiant

June 11, 2026

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Conexiant

June 11, 2026

Medical Oddities: The Economics of Shut-Eye

Sleep became a commodity, tea became a therapy, and cats got a reprieve this week.

Conexiant

June 10, 2026

Sugar-Sweetened Beverages May Raise Risk of  Hepatic Cancer Subtypes

In a pooled analysis of more than 1.5 million patients, sugar-sweetened beverages were associated with higher risks of HCC and ICC, while artificially-sweetened beverages showed no independent association with hepatic cancer.

Conexiant

June 09, 2026

Tranexamic Acid Reduces Previa Bleeding

The composite endpoint reached statistical significance, but transfusion alone did not, and the single-country design may limit applicability across populations.

Conexiant

June 09, 2026

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

A Korean cohort study found fewer kidney cancer cases among patients with type 2 diabetes who initiated sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors.

Conexiant

June 08, 2026

FDA Expands Marstacimab Indication in Hemophilia A and B

Phase 3 BASIS and BASIS KIDS data supported the expanded indication across pediatric and inhibitor-pretreated populations.

Conexiant

June 05, 2026

Poor Diet Quality Linked to Oral Cancer

Large prospective cohort data showed stronger associations among women without substantial tobacco or alcohol exposure.

Conexiant

June 05, 2026

Chemoimmunotherapy Linked to HNSCC Response

Higher pathologic response rates with chemoimmunotherapy versus immunotherapy alone call for phase 3 trials, but survival implications remain unknown.

Conexiant